Loading...
XKRX
009420
Market cap1.88bUSD
Jul 10, Last price  
57,400.00KRW
1D
3.24%
1Q
21.74%
Jan 2017
336.50%
Name

Hanall Biopharma Co Ltd

Chart & Performance

D1W1MN
XKRX:009420 chart
P/E
—
P/S
18.81
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-0.53%
Rev. gr., 5y
11.86%
Revenues
155.18b
+11.69%
82,485,563,00091,890,326,00098,682,408,000106,903,737,00087,701,600,68076,027,305,22074,228,313,77080,879,668,14080,022,559,94082,881,524,07084,230,756,08091,839,350,940108,452,042,00088,602,270,000101,594,444,000109,995,418,980134,909,838,000138,943,699,000155,184,524,000
Net income
-5.56b
L+207.96%
-1,029,708,0001,170,025,000581,952,000213,659,000-14,525,740,000-2,922,595,000-21,498,897,000-12,658,084,910-7,077,356,9502,026,026,4205,813,253,6603,300,102,19019,174,350,00019,764,499,0008,896,137,000251,473,6403,508,608,000-1,804,843,000-5,558,277,000
CFO
-2.34b
L
271,722,000-3,278,652,0004,742,178,0001,418,781,0007,413,981,1002,197,165,680-7,780,098,850-3,518,357,340-454,023,7003,950,368,12042,138,652,270-2,994,392,10020,490,918,610929,290,570839,871,90025,204,351,00029,642,920,0009,360,058,000-2,340,358,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

HANALL BIOPHARMA Co., Ltd. engages in the manufacture and sale of synthetic drug and biopharmaceuticals. It offers products such as medicine for digestion, high blood pressure, cerebrovascular disease, myocardial infarction, anti-diabetics, antibiotics, gastrointestinal, bone structure, erectile dysfunction, hives, and other pharmaceutical products. The company was founded by Byeong-Tae Kim on November 20, 1973 and is headquartered in Daejeon, South Korea.
URL
http://www.hanall.co.kr/
IPO date
Dec 18, 1989
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT